MedTrace Logo

Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer

NCT03717610 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-10-08

No results posted yet for this study

Summary

This is a feasibility single-center study to investigate the tolerability, toxicity, quality of life, morbidity, mortality of the HIPEC treatment following cytoreductive surgery for treatment of recurrent ovarian, peritoneal, and fallopian tube cancers.

Conditions

  • Ovarian Cancer Recurrent

Interventions

PROCEDURE

radical surgery with HIPEC

Straight after macroscopic radical cytoreductive surgery, an intraperitoneal hyperthermic perfusion using the open-abdomen technique will be performed with a single dose of cisplatin 100 mg/m2 administered for 90 minutes in the hyperthermic phase (41°C-43°C).

Sponsors & Collaborators

  • Uppsala University

    collaborator OTHER

  • The Netherlands Cancer Institute

    collaborator OTHER

  • Uppsala University Hospital

    lead OTHER

Principal Investigators

  • Marta Lomnytska, MD, PhD · Uppsala University, Sweden

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-04
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03717610 on ClinicalTrials.gov